[Featured Stock] Vuno Rises 5.49% on 'Sales Growth Expectations'

Vuno's stock price rose on the 1st following a corporate report from the securities industry that raised its target price, citing prospects such as the extension of the grace period for new medical technology evaluation, the visibility of entry into the U.S. market, and a reduction in the deficit in the second half of this year.

As of 9:34 a.m. that day, Vuno was trading at 31,700 KRW, up 1,650 KRW (5.49%) from the previous trading day.

Kiwoom Securities stated, "As artificial intelligence (AI) proves itself with numbers, we expect the stock price to rise as a general trend. We present Vuno as the top pick in the medical device sector," and raised Vuno's target price from 34,000 KRW to 48,000 KRW.

For the second quarter of this year, sales are expected to reach 6.8 billion KRW, an increase of 125.1% compared to the same period last year. Minsoo Shin, a researcher at Kiwoom Securities, said, "The operating profit margin for the second quarter is expected to be -52.4%, indicating a significant deficit," but added, "However, as the active expenditure for entering the U.S. market is coming to an end, changes are expected from the second half of the year."

Researcher Shin said, "The grace period for new medical technology evaluation has been extended from 2 years to 4 years (2+2 years), postponing the time when the price of DeepCARS will drop from the third quarter of next year to the third quarter of 2027." DeepCARS is a system that predicts cardiac arrest and helps manage patient prognosis. He added, "We raised the domestic and international sales forecasts for DeepCARS by reflecting the potential increase in U.S. sales due to exchange rates and the penetration rate expected to be boosted by U.S. partners."

This content was produced with the assistance of AI translation services.